Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer

BACKGROUND: Atezolizumab treatment improves survival, with manageable safety, in patients with previously treated advanced/metastatic non-small cell lung cancer. The global phase III/IV study TAIL (NCT03285763) was conducted to evaluate the safety and efficacy of atezolizumab monotherapy in a clinic...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Immunother Cancer
Main Authors: Ardizzoni, Andrea, Azevedo, Sergio, Rubio-Viqueira, Belen, Rodríguez-Abreu, Delvys, Alatorre-Alexander, Jorge, Smit, Hans J M, Yu, Jinming, Syrigos, Konstantinos, Trunzer, Kerstin, Patel, Hina, Tolson, Jonathan, Cardona, Andres, Perez-Moreno, Pablo D, Newsom-Davis, Tom
פורמט: Artigo
שפה:Inglês
יצא לאור: BMJ Publishing Group 2021
נושאים:
Clinical/Translational Cancer Immunotherapy
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7978274/
https://ncbi.nlm.nih.gov/pubmed/33737339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001865
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים